Effects of methylphenidate on children with attention deficit hyperactivity disorder: a study using clinical and multimodal approaches including go/no-go task and functional near-infrared spectroscopy

Our findings suggest that activation in the right mPFC is a viable objective neurofunctional biomarker for monitoring MPH treatment response using fNIRS. Concurrently, a multimodal assessment strategy integrating clinical evaluations, neuropsychological testing (go/no-go task), and fNIRS holds significant promise as a robust method for objectively determining the therapeutic efficacy of MPH in pediatric ADHD.